In related studies, pharmacological inhibition of ENT1 with NBTI reduces seizure severity and prolongs latency in in vivo epilepsy models, likely through enhanced extracellular adenosine levels (30, 52). This evidence concerns the gene SLC29A1 and epilepsy.